Study Group: Physicians who Treat Liver Cancer
Council Members in this Study Group: 126
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Taral PatelOncologist
MID-OHIO ONCOLOGY & HEMOTOLOGY INC
Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer,...
Rossana BerardiConsultant Medical Oncologist
UNIVERSITA' POLITECNICA DELLE MARCHERossana Berardi, MD, is a Researcher and Lecturer - Consultant Medical Oncologist in the Department of Medical Oncology at the Universita Politecnica delle Marche, Italy, since November 2005. She is involved in clinical research and GCP trials on the...
Carlos DujovneProfessor of Medicine and Director
OREGON HEALTH & SCIENCE UNIVERSITY - CCCarlos Dujovne is the Professor of Medicine, the Chairman of Kansas Foundation for Clinical Pharmacology and Therapeutics (KFCPT), Cardiovascular Division and the Director of Clinical Cardiovascular and Metabolic Risk Treatment Programs at Oregon Health...
- Sujith Kalmadi
Staff Physician
Ironwood Cancer & Research CenterSujith Kalmadi, MD, is a Staff Physician at the Ironwood Cancer and Research Center in Phoenix, Arizona. Dr. Kalmadi has previously worked as a Clinical Assistant Professor at Baylor school of Medicine in Houston, Texas, and at the Lerner School of Medicine...
- Averell Sherker
Associate Professor of Clinical Medicine
Georgetown University - CCAverell Sherker, MD, FRCP, is Director of the Center for Liver Diseases at Washington Hospital Center in Washington, DC. He is also Associate Professor of Clinical Medicine at Georgetown University. Previously, Dr. Sherker was Director of Hepatology Research...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Cost will be the tricky point...
August 22, 2009
Analysis by: Rossana Berardi, Consultant Medical Oncologist,IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com
I believe that, considering the other available agents, gefitinib could be prescribed to up to 1/3 of NSCLC patients...
-
July 2, 2009
Analysis by: Rossana Berardi, Consultant Medical Oncologist,IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com
The approval of Iressa in NSCLC, opens the way to another therapeutic option in advanced NSCLC.
-
Iressa: will it be a new therapeutic option or will it replace another existing option?
May 4, 2009
Analysis by: Rossana Berardi, Consultant Medical Oncologist,IRESSA (Gefitinib) Recommended for Approval for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com
The recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMEA recommending to grant a marketing authorisation for Iressa in NSCLC, opens the way to another therapeutic option in advanced NSCLC.
-
Another good result for Roche.
March 23, 2009
Analysis by: Rossana Berardi, Consultant Medical Oncologist,UPDATE 1-Roche's Herceptin prolongs stomach cancer survival | www.reuters.com
The results from ToGA, a large international phase III trial, showed the benefit of herceptin plus chemotherapy vs chemotherapy alone as the first therapy for patients with advanced unresectable gastric cancer.
-
A Novel Option for Management of Malignant Ascites.
March 23, 2009
Analysis by: Rossana Berardi, Consultant Medical Oncologist,COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE: SUMMARY OF POSITIVE OPINION FOR REMOVAB | www.emea.europa.eu
Catumaxomab is a trifunctional monoclonal antibody with 2 antigen-recognition sites: one for human EpCAM, a cell surface antigen expressed by a variety of epithelial tumor cells, and one for human CD3, a T-cell surface antigen. In addition, another region of the antibody binds to receptors that are expressed on other cells of the immune system.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Government/Military Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Physician - Department Chair
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Council Members who Treat Colon/Colorectal Cancer | 214 |
| Gastroenterologists (US) | 803 |
| Oncologists (US) | 2241 |
| Physicians who Treat HCV (US) | 111 |
| Gastroenterologists who Treat GERD | 380 |
| Oncologists (EU) | 761 |
| Prescribers of Pegasys | 29 |
| Pancreatic Cancer Oncologists in the U.S. | 80 |